managing-gynecologic-screening

name	managing-gynecologic-screening
description	Applies ASCCP cervical cancer screening guidelines with HPV co-testing and colposcopy indications. Use when managing cervical screening, applying ASCCP guidelines, or determining colposcopy need.
tags	["management","obstetrics-and-gynecology"]
metadata	{"author":"casemark","practice_areas":["Obstetrics","Gynecology","Maternal-Fetal Medicine"],"document_types":["Management Report"],"skill_modes":["Management","Coordination"]}

Managing Gynecologic Screening

Applies ASCCP risk-based cervical cancer screening guidelines, Bethesda System cytology classification, HPV co-testing protocols, and colposcopy indications for evidence-based cervical cancer prevention.

Why This Skill Exists

Cervical cancer is a largely preventable disease through screening and HPV vaccination. The 2019 ASCCP Risk-Based Management Consensus Guidelines replaced the prior algorithm-based approach with a risk-estimation framework where management is determined by the patient's estimated risk of CIN 3+ rather than by individual test results alone. The Bethesda System for Reporting Cervical Cytology provides the standardized terminology (ASC-US, LSIL, HSIL, AGC, etc.) that clinicians must use when documenting results.

Errors in screening management — over-screening low-risk patients, under-screening high-risk patients, or failing to refer for colposcopy when indicated — contribute to both unnecessary procedures and missed cancers. This skill ensures that every screening decision follows the ASCCP risk thresholds and is properly documented.

---

Checkpoint A: Pre-Draft Intake (Mandatory)

1. Patient age — screening recommendations vary by age group. (Default: from demographics)
2. HPV vaccination status — vaccinated patients still require screening per guidelines. (Default: from immunization record)
3. Screening history — last Pap/HPV test date and results? Any prior abnormal results? (Default: from prior lab reports)
4. HIV status — HIV-positive patients have separate screening intervals. (Default: from chart)
5. Immunosuppression status — organ transplant, chronic steroid use, other immunosuppression? (Default: from problem list)
6. Prior treatment history — LEEP, cone biopsy, cryotherapy, or hysterectomy? (Default: from surgical history)
7. Pregnancy status — Pap screening may be performed but colposcopy management differs in pregnancy. (Default: confirm)
8. DES exposure — in utero DES exposure requires specialized screening. (Default: ask if age-appropriate)

Documents to Request

• Prior Pap smear results with Bethesda classification
• HPV testing results (genotyping: HPV 16/18 vs. other high-risk types)
• Colposcopy reports and biopsy pathology
• Prior LEEP/cone operative and pathology reports
• HIV test results
• Immunization records (HPV vaccine series)

---

Step 1: Apply Age-Based Screening Intervals

Per USPSTF/ACOG/ACS/ASCCP recommendations:

Age Group	Screening Recommendation
< 21 years	No screening regardless of sexual history or HPV vaccination
21–24 years	Cytology alone every 3 years; NO HPV co-testing
25–29 years	Cytology every 3 years, OR HPV primary screening every 5 years (per ACS 2020 update)
30–65 years	Cytology + HPV co-testing every 5 years (preferred), OR cytology alone every 3 years, OR HPV primary screening every 5 years
> 65 years	Discontinue if adequate prior screening (3 consecutive negative cytology or 2 consecutive negative co-tests in prior 10 years, most recent within 5 years) and no history of CIN 2+ in prior 25 years
Post-hysterectomy (with cervix removed)	Discontinue if no history of CIN 2+ and cervix fully removed

Special populations:

• HIV-positive: Begin screening at age 21, cytology annually; co-testing every 3 years if age ≥ 30 with normal results × 3
• Immunosuppressed (non-HIV): Screen per HIV guidelines
• In utero DES exposure: Annual cytology starting at age of diagnosis

---

Step 2: Interpret Results Using the Bethesda System

Cytology Categories (Bethesda 2014)

Bethesda Category	Meaning	Clinical Significance
NILM	Negative for intraepithelial lesion or malignancy	Normal result
ASC-US	Atypical squamous cells of undetermined significance	Mildly abnormal; reflex HPV testing indicated
ASC-H	Atypical squamous cells, cannot exclude HSIL	Higher concern; colposcopy recommended
LSIL	Low-grade squamous intraepithelial lesion	Corresponds to HPV effect / CIN 1
HSIL	High-grade squamous intraepithelial lesion	Corresponds to CIN 2/3; colposcopy required
AGC	Atypical glandular cells	Requires colposcopy + endocervical curettage ± endometrial biopsy
AIS	Adenocarcinoma in situ	Requires colposcopy, ECC, and excisional procedure
SCC	Squamous cell carcinoma	Invasive cancer — urgent gynecologic oncology referral

HPV Results

• HPV negative — low risk, return to routine screening
• HPV positive (other high-risk, non-16/18) — risk depends on cytology
• HPV 16 positive — highest risk; colposcopy regardless of cytology
• HPV 18 positive — high risk; colposcopy regardless of cytology

---

Step 3: Apply the 2019 ASCCP Risk-Based Framework

Management is based on the estimated CIN 3+ risk using current and prior test results:

Estimated CIN 3+ Risk	Recommended Action
< 0.15%	Return to routine 5-year screening
0.15–0.54%	Return in 3 years for repeat testing
0.55–3.9%	Return in 1 year for repeat testing
4.0–24%	Colposcopy recommended
25–59%	Colposcopy with biopsy; treatment acceptable
60–100%	Excisional treatment recommended (LEEP or cold knife cone)

Key clinical action thresholds:

• ASC-US / HPV negative: Return in 3 years (low risk)
• ASC-US / HPV positive (non-16/18): Return in 1 year
• ASC-US / HPV 16 or 18 positive: Colposcopy
• LSIL / HPV negative (ages 25+): Return in 1 year
• LSIL / HPV positive: Colposcopy
• HSIL (any HPV result): Colposcopy; expedited treatment (LEEP) acceptable if not pregnant
• AGC: Colposcopy + ECC + endometrial biopsy (if age ≥ 35 or risk factors for endometrial cancer)

---

Step 4: Colposcopy Documentation Requirements

When colposcopy is performed, document:

1. Indication — cytology result, HPV status, ASCCP risk estimate
2. Adequacy — visualization of entire squamocolumnar junction (SCJ) — adequate vs. inadequate
3. Findings — acetowhite epithelium, punctation, mosaicism, atypical vessels, lesion size and location (clock positions)
4. Biopsy location(s) — number and clock positions of biopsies taken
5. Endocervical curettage (ECC) — performed or not, indication
6. Impression — low-grade vs. high-grade colposcopic impression
7. Pathology results — CIN 1, CIN 2, CIN 3, AIS, invasive carcinoma
8. Management plan — surveillance vs. excision based on pathology and ASCCP guidelines

---

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is the screening interval appropriate for the patient's age and risk profile?
2. Are all test results documented with Bethesda terminology for cytology and specific HPV genotype data?
3. Does the management plan match the ASCCP risk-based recommendation for the test result combination?
4. Is the colposcopy referral documented when indicated, or is the surveillance plan clearly stated?
5. Are special populations flagged — HIV, immunosuppressed, post-treatment, DES exposure?

---

Quality Audit

• Patient age documented and screening interval matches age-based recommendation
• Cytology result documented using Bethesda System terminology
• HPV result documented with genotype specificity (16, 18, other high-risk, negative)
• ASCCP risk estimate or risk category is stated
• Colposcopy referral documented when CIN 3+ risk ≥ 4%
• Colposcopy adequacy (SCJ visualization) documented when performed
• Biopsy results documented with CIN grade
• ECC performed and results documented for AGC or unsatisfactory colposcopy
• Prior abnormal results are referenced when estimating current risk
• Treatment plan (surveillance vs. excision) is stated with next follow-up date
• HIV and immunosuppression screening protocols applied when applicable
• Post-treatment surveillance documented (at 6 months, 12 months, then annually × 3 years, then every 3 years × 25 years)
• HPV vaccination status documented and vaccine offered if eligible (up to age 45)

---

Guidelines

1. Use Bethesda terminology exclusively — never write "Class II" or "mild dysplasia" in place of the standardized Bethesda terms.
2. Always pair cytology with HPV result — isolated cytology interpretation without HPV context leads to incorrect risk estimation.
3. Do not over-screen — annual Pap smears are not recommended for average-risk patients over age 30 with negative co-testing; the interval is 5 years.
4. Age 21–24 is a special group — LSIL and ASC-US in this age group are managed conservatively due to high regression rates. Do NOT perform HPV co-testing.
5. AGC triggers a broader workup — always include ECC and consider endometrial biopsy, especially in patients ≥ 35 or with abnormal bleeding.
6. Post-treatment surveillance is 25 years — patients with treated CIN 2+ remain at elevated risk for at least 25 years and must not return to standard population-based screening intervals.
7. Document the "adequate negative prior" determination when discontinuing screening at age 65 — list the specific tests and dates that meet exit criteria.